UNITY Biotechnology announced 36-week results from its Phase 2b ASPIRE trial of UBX1325 for diabetic macular edema (DME). The trial demonstrated that UBX1325 achieved visual gains non-inferior to the current standard of care, aflibercept, in patients with difficult-to-treat DME, and even outperformed aflibercept in a subgroup of patients with less severe disease at baseline. Following these results, UNITY is exploring strategic alternatives to advance its ophthalmologic assets and reduce operating costs, including a company-wide reduction in force.
These findings are potentially important for DME patients who have not responded well to existing anti-VEGF treatments. UBX1325 operates through a novel mechanism of action (BCL-xL inhibition) distinct from anti-VEGF therapy, suggesting a new avenue for treating this condition and potentially addressing an unmet need for patients resistant to current therapies. The positive results in the subgroup of patients with moderate disease (CST <400 microns) further highlight UBX1325’s potential to offer improved outcomes for a specific patient population. The 36-week data showed UBX1325’s non-inferiority to aflibercept in visual acuity gains. Importantly, a favorable safety and tolerability profile was observed, with no reports of intraocular inflammation or other serious ocular adverse events. Strategically, UNITY’s board has approved a revised operational plan focused on exploring options for UBX1325, including potential sale, licensing, or other partnerships. The company is also seeking strategic alternatives for its other assets, including a Tie2/anti-VEGF bispecific and a Tie2 agonistic antibody. This restructuring involves a significant reduction in force across the company. The strategic shift toward exploring partnerships or divestiture indicates that UNITY believes further development and commercialization of UBX1325 may be best achieved through collaboration with a company possessing an established ophthalmology presence. This decision suggests a prioritization of maximizing the therapeutic potential of UBX1325 by leveraging external resources and expertise. The restructuring also underscores UNITY’s commitment to preserving capital while pursuing the most promising path forward for its assets.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
